Phase II study of SNJ-2022; An exploration study in patients with primary open angle glaucoma or ocular hypertensio
- Conditions
- Primary open-angle glaucoma (POAG) or Ocular hypertension (OH)
- Registration Number
- JPRN-UMIN000019142
- Lead Sponsor
- Senju Pharmaceutical co.,ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Not provided
1)Any active ocular disease other than glaucoma or OH 2)Active retinal disease 3)History of keratorefractive surgery, filtering surgery, trabeculotomy in the study eye 4)Ocular surgery within 3 months in the study eye 5)Use of contact lenses 6)Allergy or serious side effect to alpha2-adrenergic agonist 7)Use of alpha-adrenoceptor agonist, alpha-adrenoceptor antagonist, beta-adrenergic agonist, beta-adrenoceptor antagonist, MAO inhibitor, adrenergic-augmenting psychotropic drugs, Central Nervous System Depressant 8)Patient with Impaired liver function, kidney disorder, depression, raynaud disease, thromboangiitis obliterans, orthostatic hypotension, cerebrovascular occlusion, coronary vessel occlusion, compromised circulation of serious cardiovascular disease 9)Women who were pregnant, nursing or who were of childbearing potential, or planning a pregnancy 10)Highly visual field loss 11)Corneal abnormalities that would preclude accurate readings with an applanation tonometer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method